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ABSTRACT 
A solution of propyl gallate(0.01 mol) in ethanol and hydrazine hydrate (0.01 mol) was refluxed for 4 hours. The excess solvent was distilled off 
under reduced pressure. The cooled residual mass was washed with distilled water. It was filtered and dried. The crude product was 
recrystallised from methanol to yield galloylhydrazide, Carbon disulfide (2 ml) was added drop wise to an ice cooled solution of KOH (2g) in 
ethanol (20 ml) containing the acid hydrazide 4 (0.02 mole), then the reaction mixture was stirred at room temperature 2h . After dilution with 
ethanol the solid precipitated was washed twice with ether. To the solid obtained (1 g), 10% KOH (20 ml) was added then the r eaction mixture 
was refluxed for 4 hr, cooled, acidified with conc. HCl. The resulting solid was filtered washed with water, dried and crystallized. A mixture of 
(0.97g, 0.005mol) of 5-(5-sulfanyl- 1,3,4-oxadiazol-2-yl)benzene-1,2,3-triol and (0.005mol) of different aryl or alkyl  halides were refluxed in 
25ml of pyridine solution for 3.5 hours. The resultant mixture was cooled and poured into crushed ice. The solid mass is thus separated out was 
dried and recrystallized from ethanol. Synthesized derivatives purity were checked by TLC, Melting point & characterized by F T-IR, Mass, NMR 
spectroscopic techniques. Synthesized derivatives were evaluated for anti-microbial activity. 
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INTRODUCTON: 
During the 19th century, the French scientist Louis Paster and 
German  physician demonstrated the roll of bacteria as 
pathogens the discovery of compound produce by bacteria 
and fungi have shown their the lethal effect to other bacteria 
led to development of  antibiotics1,2 Bacteria are free living, 
microscopic, unicellular organism capable of performing all 
the essential functions of life i.e. growth, metabolism and 
reproduction .They possess both deoxyribonucleic acid 
(DNA) and ribonucleic acid (RNA) and lack of chlorophyll. 
Bacteria have been placed in a kingdom separate from the 
animal and plant kingdoms. Scientist use various system for 
classifying bacteria based on different, shapes, dependence 
on oxygen and by staining techniques. 
Agents that inhibit bacterial cell wall synthesis: 
This includes β-lactamase antibiotics, like Ampicilin and 
Cephalosporines and Azole derivatives. β-lactamase inhibits 
D-alanyl-D-alanine transpeptidase activity by acylation, 
forming stable esters with opened lactum ring  attached to 
hydroxyl group of the enzymes active site. 
Agents that interfere with DNA-RNA synthesis:  
Quinolones, are bactericidals and they inhibit DNA gyrase 
synthesis,Eg. Ciprofloxacine, norfloxacine, sparfloxacine. 
Sulphonamides inhibit microbial growth by inhibiting P-
aminobenzoic acid (PABA) involved in folic acid synthesis. 
Antimetabolites: 
 An antimetabolite is a chemical that inhibits the use of a 
metabolite, which is another chemical that is part of normal 
metabolism.21 Such substances are often similar in structure 
to the metabolite that they interfere with, such as the 
antifolates that interfere with the use of folic acid. 
Agents that interfere with protein synthesis:  
This class includes, Tetra cyclones, which block and binds 
aminoacyl receptor site of tRNA, Chloramphinicol, and 
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Erythromycines, binds p-sites of the 50S ribosomal subunit 
and inhibit translation.19 
Oxadiazoles 
The 1, 2, 3-isomer is unstable and reverts to the diazoketone 
tautomer3Oxadiazoles were discovered against the 
schistosomiasis-causing fluke in the year 2008. It did not 
show any negative effects on humans. The stable oxadiazoles 
appear in a variety of pharmaceutical drugs including 
raltegravir (anti-retroviral), butalamine, fasiplon, oxolamine, 
and pleconaril. Tiodazosin, nosapidil, furamizole are other 
examples.4 
Naturally Ocurring Oxadiazoles:  
There are only few examples of natural products with 
oxadiazole core or a structure based on it. One among this is 
phidianidines A and B (Figure 1), this is a 3-substituted 
indole alkaloid. Phidianidines A and B have been isolated by 
Carbone et al. from the aeolidopisthobranchPhidiana 
militaris.5  
Chemistry  
Due to the presence of a heteroatom in the ring, oxadiazole 
shows inductive effect and thus it is considered to be a weak 
base. It consists of 2 pyridine like nitrogen, due to which it 
exhibits conjugate diene type character. Electrophillic 
substitution at carbon is very difficult in this case due to less 
electron density which is mainly due to the presence of 
pyridine like nitrogen in the ring that shows electron 
withdrawal effect.  
MATERIAL AND METHODS: 
1. SYNTHETIC PROCEDURE: 
1.1 General procedure for preparation of 5-[5-
(substitutedsufanyl)-1,3,4-oxadiazole-2-
yl]benzene-1,2,3-triol (iva-j) 
A mixture of (0.97g, 0.005mol) of 5-(5-sulfanyl- 1,3,4-
oxadiazol-2-yl)benzene-1,2,3-triol and (0.005mol) of 
different aryl or alkyl  halides were refluxed in 25ml of 
pyridine solution for 3.5 hours. The resultant mixture was 
cooled and poured into crushed ice. The solid mass is thus 
separated out was dried and recrystallized from ethanol. 
Step: 4.2 Synthesis of   5-{5-[(4-methylphenyl)sulfanyl]-
1,3,4-oxadiazol-2-yl}  benzene-1,2,3-triol (iva) for procedure 
refer step 3, aryl halide (4-methylbromo-benzene) was used. 
OH
OH
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CH3
propyl 3,4,5-trihydroxybenzoate /(propyl gallate)
NH2NH2.H2O EtOH, Reflux, 4 hr.
OH
OH
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O
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Where R= iva=Ar-CH3ivb=Ar-OCH3ivc=Ar-OH      ivd=Ar-
NO2ive=Ar-C2H5 ivf=CH3ivg=  -C2H5               ivh= C3H7         ivi=Ar-
NH2ivj=Phenyl 
 
5-(5-sulfanyl-1,3,4-oxadiazol-2-yl)b
enzene-1,2,3-triol
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Step: 4.3Synthesis of   5-{5-[(4-methoxyphenyl)sulfanyl]-1,3,4-oxadiazol-2-yl}benzene-1,2,3-triol(ivb) for procedure refer step 
3, aryl halide (4-methoxylbromo benzene) was used. 
5-(5-sulfanyl-1,3,4-oxadiazol-2-yl)b
enzene-1,2,3-triol
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Step: 4.4Synthesis of   5-{5-[(4-hydroxyphenyl)sulfanyl]-1,3,4-oxadiazol-2-yl}benzene -1,2,3- 
triol(ivc) for procedure refer step 3, aryl halide (4-hydroxy bromo benzene) was  
used. 
5-(5-sulfanyl-1,3,4-oxadiazol-2-yl)b
enzene-1,2,3-triol
OH
OH
OH
O
N
N
SH
HydroxyPh-Br
pyridine, reflux
OH
OH
OH
O
N
N
S
OH
(iii) (ivc)
5-{5-[(4-hydroxyphenyl)sulfanyl]-1,3,4-oxadiazol-2-yl}
benzene-1,2,3-triol
 
Step: 4.5Synthesis of   5-{5-[(4-nitrophenyl)sulfanyl]-1,3,4-oxadiazol-2-yl}benzene-1,2,3-triol  
(ivd) for procedure refer step 3, aryl halide (4-nitro-bromobenzene) was used 
 
5-(5-sulfanyl-1,3,4-oxadiazol-2-yl)b
enzene-1,2,3-triol
OH
OH
OH
O
N
N
SH
NitroPh-Br
pyridine, reflux
OH
OH
OH
O
N
N
S
NO2
(iii) (ivd)
5-{5-[(4-nitrophenyl)sulfanyl]-1,3,4-oxadiazol-2-yl}
benzene-1,2,3-triol
 
Step: 4.6Synthesis of   5-{5-[(4-ethylphenyl)sulfanyl]-1,3,4-oxadiazol-2-yl}benzene-1,2,3-triol  
(ive) for procedure refer step 3, aryl halide (4-ethyl-bromo benzene) was used. 
5-(5-sulfanyl-1,3,4-oxadiazol-2-yl)b
enzene-1,2,3-triol
OH
OH
OH
O
N
N
SH
ethylPh-Br
pyridine, reflux
OH
OH
OH
O
N
N
S
C2H5
(iii) (ive)
5-{5-[(4-ethylphenyl)sulfanyl]-1,3,4-oxadiazol-2
-yl}benzene-1,2,3-triol
 
Step: 4.7Synthesis of   5-[5-(methylsulfanyl)-1,3,4-oxadiazol-2-yl]benzene-1,2,3-triol (ivf) for  
procedure refer step 3 alkyl halide (methyl-bromo) was used. 
 
5-(5-sulfanyl-1,3,4-oxadiazol-2-yl)b
enzene-1,2,3-triol
OH
OH
OH
O
N
N
SH
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pyridine, reflux
OH
OH
OH
O
N
N
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(iii) (ivf)
5-[5-(methylsulfanyl)-1,3,4-oxadiazol-2-yl]benz
ene-1,2,3-triol
 
Step: 4.8 Synthesis of   5-[5-(ethylsulfanyl)-1,3,4-oxadiazol-2-yl]benzene-1,2,3-triol (ivg) for  
procedure refer step 3 alkyl halide (ethyl-bromo) was used. 
5-(5-sulfanyl-1,3,4-oxadiazol-2-yl)b
enzene-1,2,3-triol
OH
OH
OH
O
N
N
SH
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pyridine, reflux
OH
OH
OH
O
N
N
S C2H5
(iii) (ivg)
5-[5-(ethylsulfanyl)-1,3,4-oxadiazol-2-yl]benzen
e-1,2,3-triol
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Step: 4.9 Synthesis of   5-[5-(propylsulfanyl)-1,3,4-oxadiazol-2-yl]benzene-1,2,3-triol (ivh) for  
procedure refer step 3 alkyl halide (propyl-bromo) was used 
5-(5-sulfanyl-1,3,4-oxadiazol-2-yl)b
enzene-1,2,3-triol
OH
OH
OH
O
N
N
SH
propyl-Br
pyridine, reflux
OH
OH
OH
O
N
N
S C3H7
(iii) (ivh)
5-[5-(propylsulfanyl)-1,3,4-oxadiazol-2-yl]benz
ene-1,2,3-triol
 
Step: 4.10Synthesis of   5-{5-[(4-aminophenyl)sulfanyl]-1,3,4-oxadiazol-2-yl}benzene-1,2,3- 
triol(ivi) for procedure refer step 3, aryl halide (4-amino-bromo benzene) was used 
5-(5-sulfanyl-1,3,4-oxadiazol-2-yl)b
enzene-1,2,3-triol
OH
OH
OH
O
N
N
SH
aminoPh-Br
pyridine, reflux
OH
OH
OH
O
N
N
S
NH2
(iii) (ivi)
5-{5-[(4-aminophenyl)sulfanyl]-1,3,4-oxadiazol-2-yl}
benzene-1,2,3-triol
 
Step: 4.11Synthesis of   5-[5-(phenylsulfanyl)-1,3,4-oxadiazol-2-yl]benzene-1,2,3-triol (ivj) for  
procedure refer step 3, aryl halide (bromo benzene) was used. 
5-(5-sulfanyl-1,3,4-oxadiazol-2-yl)b
enzene-1,2,3-triol
OH
OH
OH
O
N
N
SH
Ph-Br
pyridine, reflux
OH
OH
OH
O
N
N
S
(iii) (ivj)
5-[5-(phenylsulfanyl)-1,3,4-oxadiazol-2-yl]ben
zene-1,2,3-triol
 
Table 1 physiochemical data of synthesized compound (iva-j) 
Compound % yield Rf value Mol. formula Mol. weight 
iva 81.64 0.63 C15H12N2O4S 316.33 
ivb 73.27 0.82 C15H12N2O5S 332.33 
ivc 77.33 0.74 C14H10N2O5S 318.30 
ivd 61.01 0.79 C14H19N3O6S 347.30 
ive 69.82 0.81 C16H14N2O4S 330.35 
ivf 78.62 0.58 C9H8N2O4S 240.23 
ivg 76.23 0.68 C10H10N2O4S 254.26 
ivh 65.73 0.66 C11H12N2O4S 268.28 
ivi 71.98 0.85 C14H11N3O4S 317.31 
ivj 91.82 0.71 C14H10N2O4S 302.30 
Solvent system for TLC- ethyl acetate: n-hexane (65:35) 
 
Screening of Antibacterial Activity: 
All the compounds synthesized in the present investigation 
were screened for their anti-bacterial activity by Cup plate 
Method. Antibacterial activities were tested on nutrient 
medium against, Staphylococcus aureus, and Escherchia coli 
which are representative types of gram positive and gram 
negative organisms respectively. The antibacterial activity of 
the compounds was assessed by disc-diffusion method.  
Preparation of Nutrient Agar Media: 
Media Composition and Procedure: 
The nutrient agar media was prepared by using the 
following ingredients. 
1) Peptone (Bacteriological)                                  20 gm 
2) Beef extract (Bacteriological)                            5 gm 
3) Sodium chloride                                                    5 gm 
4) Agar Agar                                                                20 gm 
5) Distilled water up to                                            1000 ml. 
Weighed quantities of peptone and beef extract were 
dissolved in distilled water by gentle warming and then 
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specified amount of agar was dissolved by heating on water 
bath. Then the pH of the solution was adjusted to7.2 to7.4 by 
adding the sodium chloride and the volume of the final 
solution was made up to 1000 ml with distilled water. Then 
it was transferred in to a suitable container, plugged with 
non-adsorbent cotton and the media was sterilized by in 
autoclave at 1210C for 20 minutes at 15 lbs pressure. 
Preparation of Test Solutions: 
10 mg of the compound was dissolved in 10 ml of DMF. From 
this 1 ml of solution was taken and diluted up to 10 ml with 
DMF. Now the concentration of the test solution was 100 
g/ml. From the stock solution 1ml of solution was taken 
and diluted with 1ml of DMF now the concentration is 
50g/ml. 
Preparation of standard antibiotic solution: 
Amoxicillin was used as standard antibiotics for comparison 
and solutions were prepared by using sterile water, as they 
were water-soluble. The solutions are diluted by using 
sterile water so that the concentrations of the solutions were 
100 g/ml and 50 g/ml. 
Preparation of Discs: 
Discs of 6-7 mm in diameter were punched from NO: 1 
Whattmann filter paper with sterile cork borer of same size. 
These discs were sterilized by keeping in oven at 1400C for 
60 minutes. Then standard and test solutions were added to 
each disc and discs were air-dried. 
Method of Testing: 
The sterilized media was cooled to 450C with gentle shaking 
to bring about uniform cooling and then inoculated with 18-
24 hrs old culture under aseptic conditions, mixed well by 
gentle shaking. This was poured in to sterile Petri dishes 
(properly labeled) and allowed the medium to set. After 
solidification all the Petri dishes were transferred to laminar 
flow unit. Then the discs which were previously prepared 
were carefully kept on  
the solidified media by using sterilized forceps. These Petri 
dishes were kept as it is for one-hour diffusion at room 
temperature and then for incubation at 370C for 24 hours in 
an incubator. 
The extent diameter of inhibition after 24 hours was 
measured as the zone of inhibition in millimeters. 
 
 
RESULT AND DISCUSSION: 
Table 1: anti-bacterial activity data of synthesized compounds 
Sr.No compound Concentration μg/ml E.coli S.Aureus 
1 iva 50 9 10 
 100 11 10 
2 ivb 50 9 11 
 100 12 11 
3 ivc 50 9 10 
 100 13 14 
4 ivd 50 10 12 
 100 13 14 
5 ive 50 10 11 
 100 12 12 
6 ivf 50 9 8 
 100 10 9 
7 ivg 50 11 11 
 100 13 12 
8 ivh 50 10 9 
 100 11 10 
9 ivi 50 20 19 
 100 22 22 
10 ivj 50 10 11 
 100 11 12 
11 Amoxicillin 50 24 25 
 100 25 25 
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Zone of inhibition of synthesized compounds: 
  Note:  6-8 mm poor activity, 9-11 mm moderate activity, 12-15 above good. 
                  Strain of E.Coli                             strain of  S.Aureus                 strain of  E.Coli                 strain of S.Aureus 
                                         Conc. 50µg/ml                                                                              Conc. 100µg/ml 
 
(Zone of inhibition of comp iva) 
                    Strain of E.Coli                             strain of S.Aureus                 strain of  E.Coli                 strain of S.Aureus 
                                         Conc. 50µg/ml                                                                              Conc. 100µg/ml 
 
( Zone of inhibition of comp ivb) 
              Strain of E.Coli                             strain of S.Aureus                 strain of  E.Coli                 strain of S.Aureus 
                                         Conc. 50µg/ml                                                                              Conc. 100µg/ml 
 
                                                                ( Zone of inhibition of comp ivc) 
Fig: 5.18 -Petri dish of compound iva to ivc 
                    Strain of E.Coli                             strain of S.Aureus                 strain of  E.Coli                 strain of S.Aureus 
                                         Conc. 50µg/ml                                                                              Conc. 100µg/ml 
 
( Zone of inhibition of comp ivd) 
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               Strain of E.Coli                             strain of S.Aureus                 strain of  E.Coli                 strain of S.Aureus 
                                         Conc. 50µg/ml                                                                              Conc. 100µg/ml 
 
(fig:5.16 Zone of inhibition of comp ive) 
                     
        Strain of E.Coli                             strain of S.Aureus                 strain of  E.Coli                 strain of S.Aureus 
                                         Conc. 50µg/ml                                                                              Conc. 100µg/ml 
 
(Zone of inhibition of comp ivf)  
Fig: 5.19 -Petri dish of compound ivd to ivf 
 
Strain of E.Coli                             strain of S.Aureus                 strain of  E.Coli                 strain of S.Aureus 
                                         Conc. 50µg/ml                                                                              Conc. 100µg/ml 
 
                                                                ( Zone of inhibition of comp ivg) 
 
               Strain of E.Coli                             strain of S.Aureus                 strain of  E.Coli                 strain of S.Aureus 
                                         Conc. 50µg/ml                                                                              Conc. 100µg/ml 
 
                                                                            (Zone of inhibition of comp ivh) 
Strain of E.Coli                             strain of  S.Aureus                 strain of  E.Coli                 strain of S.Aureus 
                                         Conc. 50µg/ml                                                                              Conc. 100µg/ml 
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(Zone of inhibition of comp ivi) 
Fig: 5.20 -Petri dish of compound ivg to ivi 
Strain of E.Coli                             strain of S.Aureus                 strain of  E.Coli                 strain of S.Aureus 
                                         Conc. 50µg/ml                                                                              Conc. 100µg/ml 
 
(Zone of inhibition of comp ivb) 
 
Strain of E.Coli                             strain of S.Aureus                 strain of  E.Coli                 strain of S.Aureus 
                                         Conc. 50µg/ml                                                                              Conc. 100µg/ml 
 
Fig: 5.21 -Petri dish of compound ivj & Amoxicillin(Standard) 
 
CONCLUSION: 
All the synthesized compounds were light creamish to 
brown coloured crystalline solids. Most of the compounds 
are freely soluble in chloroform and other solvents like 
methanol, ethanol. The melting point of the compounds was 
in the range of 152ºC to 251ºC. All synthesize compounds 
were tested for the preliminary tests, physical constants and 
TLC. All structures of final compound were confirmed by IR 
and 1HNMR spectra as well as Mass spectra. Determination 
of Zone of inhibition of synthesized compounds against 
amoxicilline as standard compound were used compound ivi 
was near to significant with standard compound. 
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